首页 | 本学科首页   官方微博 | 高级检索  
     

通心络胶囊联合卡托普利治疗高血压合并冠心病的疗效观察
引用本文:谢志贤,高正章. 通心络胶囊联合卡托普利治疗高血压合并冠心病的疗效观察[J]. 临床合理用药杂志, 2012, 5(3): 61-62
作者姓名:谢志贤  高正章
作者单位:1. 上海市奉贤区四团社区卫生服务中心,201412
2. 上海市奉贤区医学会,201412
摘    要:目的观察通心络胶囊联合卡托普利治疗高血压合并冠心病的疗效。方法选取2009年1月—2011年10月在本中心老年病房住院治疗的高血压合并冠心病患者79例,随机分为两组,治疗组40例,采用通心络胶囊加卡托普利治疗;对照组39例,给予复方丹参片加卡托普利治疗,两组疗程均为12周。治疗前后观察临床症状的变化,检测血压、心电图、血脂、血糖等指标,并作为临床疗效的评价指标,观察两组疗效。结果治疗组临床症状与心电图改善的总有效率分别为77.5%、75.7%,对照组分别为56.4%、52.8%,两组比较差异有统计学意义(P<0.05);两组血糖和血脂的变化,治疗组也明显优于对照组(P<0.05);两组降压效果基本相同,差异无统计学意义(P>0.05)。结论通心络胶囊联合卡托普利治疗高血压合并冠心病的疗效要优于复方丹参片加卡托普利,值得临床推广应用。

关 键 词:通心络胶囊  卡托普利  高血压  冠心病

Clinical Control Study of Hypertension with Coronary Heart Disease Treated by Tongxinluo Capsule Combined with Captopril
XIE Zhi-xian,GAO Zheng-zhang. Clinical Control Study of Hypertension with Coronary Heart Disease Treated by Tongxinluo Capsule Combined with Captopril[J]. Chinese Journal of Clinical Rational Drug Use, 2012, 5(3): 61-62
Authors:XIE Zhi-xian  GAO Zheng-zhang
Affiliation:(Fengxian District Situan Community Health Center,Shanghai 201412,China )
Abstract:Objective To investigate the clinical efficacy of treatment of hypertension and coronary heart disease by Tongxinluo capsule combined with captopril.Methods Select 79 patients with hypertension and coronary heart disease treated in the elderly wards of the Center from January 2009 to October 2011 as the study object.They were randomly divided into two groups.There are 40 patients in the treatment group,treated with TXL capsule and captopril.There are 39 patients in the control group,treated with Fufang Danshen Pian and captopril.Both groups were treated for 12 weeks.Observe the change of clinical symptoms before and after treatment.Check blood pressure,ECG,blood fat,blood sugar and other indicators and were used as the evaluation indicators of clinical efficacy.Relevant data is subject to statistical analysis.Results The treatment group:the total effective rate of improving clinical symptoms and ECG is 77.5% and 75.7% respectively and that of the control group is 56.4% and 52.8% respectively,with a significant difference between the two groups(P〈0.05);regarding the change of blood sugar and blood fat,the treatment group was significantly better than the control group(P〈0.05);the antihypertensive effect of both groups are basically the same,without significant difference(P〈0.05).Conclusion The therapeutic effectiveness of treating hypertension and coronary heart disease by Tongxinluo capsule combined with captopril is better than that by Fufang Danshen Pian and captopril,which is worthy of clinical application.
Keywords:Tongxinluo capsule  Captopril  Hypertension  Coronary heart disease
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号